Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT00180947
Phase
PHASE2
Status
Unknown

Conditions

  • Ewing Tumor
  • Medulloblastomas
  • Neoplasms, Connective and Soft Tissue
  • Neuroblastomas
  • Osteosarcomas
  • Rhabdomyosarcomas

Eligibility Criteria

Sex
ALL
Age
12 Months - 25 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase II study to determine the antitumor activity of Vinorelbine and Cyclofosfamide association among patients with refractory tumours or in relapse with rhabdomyosarcomas and other soft tissue tumours, Ewing tumours, osteosarcomas, neuroblastomas or medulloblastomas.

Key Dates

Start date
Jun 30, 2003
Status verified
Sep 2006

Study Design

Enrollment
210 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the antitumor activity of Vinorelbine and oral Cyclofosfamide association in refractory tumours or in relapse

Central Contacts

Related Studies